Amylin Pharmaceuticals Announces Public Offering of Common Stock
August 30 2005 - 8:30AM
PR Newswire (US)
SAN DIEGO, Aug. 30 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced a public
offering of 5,068,138 shares of common stock at a price of $31.00
per share under shelf registration statements previously filed and
declared effective by the Securities and Exchange Commission (SEC).
Net proceeds to Amylin are expected to be approximately $152
million. A prospectus supplement relating to the offering will be
filed with the SEC by Amylin, and will be available along with the
base prospectuses filed with the SEC in connection with the shelf
registrations, on the SEC's website at http://www.sec.gov/.
Goldman, Sachs & Co. is the sole underwriter for this offering.
Printed copies of the prospectus supplement and base prospectuses
relating to the offering may also be obtained, when available, from
Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad
Street, New York, New York 10004, Phone: 212-902-1000). This
announcement is neither an offer to sell nor a solicitation of an
offer to buy, nor shall there be any sale of, these securities in
any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state. The common stock is being
offered in connection with a distribution by the issuer and
represents a new financing. Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark
G. Foletta Vice President, Finance and Chief Financial Officer of
Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024